{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:07:18Z","timestamp":1759496838942,"version":"3.37.3"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR150085","RP190570"],"award-info":[{"award-number":["RR150085","RP190570"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The coronavirus disease 2019 (COVID-19) has resulted as a global pandemic. The World Health Organization announced the most promising drugs in SOLIDARITY for the global trial, and several other drugs are under investigation through ongoing clinical trials to prove the effectiveness and safety of potential therapeutics. Here, we depicted the safety profile of these drugs and investigated their associated adverse events (AEs). We observed the associated AEs in different organs\/systems, especially in skin and subcutaneous tissue, immune system and musculoskeletal and connective tissue. Furthermore, we observed strong bias of AEs in different groups of sex and age. Our study provides knowledge of the toxicity of potential COVID-19 drugs. While these drugs hold promise to fight the global pandemic, healthcare providers should pay attention to AEs to maximize the treatment benefit while minimizing toxicity.<\/jats:p>","DOI":"10.1093\/bib\/bbaa234","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T19:12:32Z","timestamp":1598469152000},"page":"1232-1238","source":"Crossref","is-referenced-by-count":10,"title":["Adverse events associated with potential drugs for COVID-19: a case study from real-world data"],"prefix":"10.1093","volume":"22","author":[{"given":"Ying","family":"Jing","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leng","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"2021032314373560700_ref1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa2005412","article-title":"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington","volume":"21","author":"McMichael","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314373560700_ref2","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"2021032314373560700_ref3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science (80-)"},{"key":"2021032314373560700_ref4","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314373560700_ref5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314373560700_ref6","first-page":"1","article-title":"Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19","volume":"94","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2021032314373560700_ref7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/pds.4970","article-title":"Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems","volume":"29","author":"Dijkstra","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021032314373560700_ref8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2021032314373560700_ref9","first-page":"1","article-title":"A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19","author":"Zhou","year":"2020","journal-title":"ChemRxiv"},{"key":"2021032314373560700_ref10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"2021032314373560700_ref11","first-page":"1","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314373560700_ref12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314373560700_ref13","first-page":"1","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"6736","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2021032314373560700_ref14","doi-asserted-by":"crossref","first-page":"2000524","DOI":"10.1183\/13993003.00524-2020","article-title":"Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study","volume":"55","author":"Du","year":"2020","journal-title":"Eur Respir J"},{"key":"2021032314373560700_ref15","first-page":"1\u20139","article-title":"Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19","author":"Huang","year":"2020","journal-title":"Natl Sci Rev"},{"key":"2021032314373560700_ref16","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021032314373560700_ref17","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2021032314373560700_ref18","first-page":"287\u2013296","article-title":"Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review","volume":"173","author":"Hernandez","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021032314373560700_ref19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","volume":"26","author":"Chorin","year":"2020","journal-title":"Nat Med"},{"key":"2021032314373560700_ref20","first-page":"1","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"2021032314373560700_ref21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology ALLAN","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol Rev"},{"key":"2021032314373560700_ref22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/bmj.39503.424653.80","article-title":"Prescribing for older people","volume":"336","author":"Milton","year":"2008","journal-title":"BMJ"},{"key":"2021032314373560700_ref23","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2018.78.3290","article-title":"Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology","volume":"36","author":"Ozdemir","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021032314373560700_ref24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tips.2009.12.001","article-title":"Gender differences in drug toxicity","volume":"31","author":"Nicolson","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"2021032314373560700_ref25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021032314373560700_ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021032314373560700_ref27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor\u2013related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"2021032314373560700_ref28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden","volume":"5","author":"Bomze","year":"2019","journal-title":"JAMA Oncol"},{"key":"2021032314373560700_ref29","first-page":"1\u201332","article-title":"Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the U.S. coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET)","author":"Kim","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021032314373560700_ref30","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13085","article-title":"Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes","author":"Rajpal","year":"2020","journal-title":"J Diabetes"},{"key":"2021032314373560700_ref31","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13091","article-title":"Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis","author":"Aggarwal","year":"2020","journal-title":"J Diabetes"},{"key":"2021032314373560700_ref32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"2021032314373560700_ref33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"2021032314373560700_ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2021032314373560700_ref35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/2\/1232\/36654857\/bbaa234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/2\/1232\/36654857\/bbaa234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T03:56:00Z","timestamp":1668052560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/22\/2\/1232\/5917051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,2]]},"published-print":{"date-parts":[[2021,3,22]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa234","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"type":"print","value":"1467-5463"},{"type":"electronic","value":"1477-4054"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,10,2]]}}}